Carvedilol modulates in vitro lipopolysacchalride-induced interleukin-10 production in monocytic cells

Acta Cardiologica Sinica

Volumn 19, Issue 2, 2003, Pages 83-92

  Cheng, Shu Meng ^a,b   Yang, Shih Ping ^a   Tsao, Den Ping ^a   Ho, Ling Jun ^a   Lai, Jenn Haung ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Carvedilol; Interleukin 10; U937 cells

Indexed keywords

CARVEDILOL; INTERLEUKIN 10; LABETALOL; LIPOPOLYSACCHARIDE;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CELL STRAIN U937; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; MONOCYTE;

EID: 0042242563     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Ruffolo RR Jr, Feuerstein GZ. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc Drugs Ther 1997;11:247-56.
2. Yue TL, Mckenna PJ, Lysko PG, et al. SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant. Eur J Pharmacol 1994;251:237-43.
3. Van der Does R, Hauf-Zachariou U, Pfarr E, et al. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. Am J Cardiol 1999;83:643-9.
4. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997;349:375-80.
5. Matsuda Y, Akita H, Terashima M, et al. Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J 2000;140:753-9.
6. Capper EA, Roshak AK, Bolognese BJ, et al. Modulation of human monocyte activities by tranilast, SB 252218, a compound demonstrating efficacy in restenosis. J Pharmacol Exp Ther 2000;295:1061-9.
7. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
8. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999;138:S419-20.
9. Howard M, O'Garra A, Ishida H, et al. Biological properties of interleukin 10. J Clin Immunol 1992;12:239-47.
10. Donnelly RP, Dickensheets H, Finbloom DS. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res 1999;19:563-73.
11. De Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
12. Ho LJ, Wang JJ, Shaio MF, et al. Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J Immunol 2001;166:1499-506.
13. Hansson GK, Jonasson L, Seifert PS, Stemme S. Immune mechanisms in atherosclerosis. Arteriosclerosis 1989;9:567-78.
14. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991;64:5-15.
15. Wakkach A, Cottrez F, Groux H. Can interleukin-10 be used as a true immunoregulatory cytokine? Eur Cytokine Netw 2000;11:153-60.
16. De Waal Malefyt R, Haanen J, Spits H, et al. Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histo-compatibility complex expression. J Exp Med 1991;174:915-24.
17. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Thl cells. J Immunol 1991;146:3444-51.
18. De Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
19. Fiorentino DF, Zlotnik A, Mosmann TR, et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815-22.
20. Uyemura K, Demer LL, Castle SC, et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996;97:2130-8.
21. Mallat Z, Heymes C, Ohan J, et al. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999;19:611-6.
22. Rider PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
23. Louis WJ, McNeil JJ, Workman BS, et al. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. J Cardiovasc Pharmacol 1987;10:S89-93.
24. Terkeltaub RA. IL-10: An "immunologic scalpel" for atherosclerosis? Arterioscler Thromb Vasc Biol 1999;19:2823-5.
25. Pinderski Oslund LJ, Hedrick CC, Olvera T, et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999;19:2847-53.
26. Oberholzer A, Oberholzer C, Moldawer LL. Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med 2002;30:S58-63.
27. Nelson S. Novel nonantibiotic therapies for pneumonia: cytokines and host defense. Chest 2001;119:419S-25S.
28. Greenberger MJ, Strieter RM, Kunkel SL, et al. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995;155:722-9.